Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Petiveria alliacea extract, branded as Esperanza, is a standardized phytomedicine developed by Hospital Universitario San Ignacio in collaboration with Pontificia Universidad Javeriana. The drug is an aqueous extract obtained from the leaves of the Petiveria alliacea plant, produced under GMP conditions. Its primary mechanism of action involves the inhibition of tumor metabolism by disrupting both glycolysis and oxidative phosphorylation (OXPHOS). It is currently being evaluated in Phase Ib/II clinical trials as a combination therapy with standard chemotherapy for patients with metastatic gastrointestinal tumors (including gastric, colorectal, pancreatic, and biliary tract cancers) and acute leukemias (AML and ALL).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on petiveria alliacea extract (Hospital Universitario San Ignacio).